Evaluation of the impact of the recent controversy over statins in France: The EVANS study

Archives of Cardiovascular Diseases

Volumn 106, Issue 10, 2013, Pages 511-516

  Saib, Anis ^a   Sabbah, Laurent ^a,b   Perdrix, Ludivine ^a   Blanchard, Didier ^a   Danchin, Nicolas ^a   Puymirat, Etienne ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Adherence; Cost effectiveness; Prevention; Statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHEMOPROPHYLAXIS; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; PATIENT COMPLIANCE; PHYSICIAN; PRIMARY PREVENTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT WITHDRAWAL;

ADHERENCE; ADHÉRENCE; BMI; BODY MASS INDEX; CABG; CORONARY ARTERY BYPASS GRAFT; COST-EFFECTIVENESS; COÛT EFFICACITÉ; LDL; LOW-DENSITY LIPOPROTEIN; MI; MYOCARDIAL INFARCTION; PCI; PERCUTANEOUS CORONARY INTERVENTION; PREVENTION; PRÉVENTION; STATINES; STATINS;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; FRANCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTENTION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84886439011     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2013.06.053     Document Type: Article

References (24)

1. P. Amarenco, J. Labreuche, P. Lavallee, and P.J. Touboul Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis Stroke 35 2004 2902 2909
2. J. Armitage, L. Bowman, and K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
3. M. Briel, G.G. Schwartz, and P.L. Thompson Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials JAMA 295 2006 2046 2056
4. P.M. Kearney, L. Blackwell, and R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
5. J.R. Kizer, C. Madias, and B. Wilner Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Am J Cardiol 105 2010 1289 1296
6. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
7. J.J. Brugts, T. Yetgin, and S.E. Hoeks The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials BMJ 338 2009 b2376
8. B. Mihaylova, J. Emberson, and L. Blackwell The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
9. K.K. Ray, S.R. Seshasai, and S. Erqou Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants Arch Intern Med 170 2010 1024 1031
10. B.J. Kelly, A.E. Leader, D.J. Mittermaier, R.C. Hornik, and J.N. Cappella The HPV vaccine and the media: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer? Patient Educ Couns 77 2009 308 313
11. P. Tuppin, P. Ricci-Renaud, and C. de Peretti Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010 Arch Cardiovasc Dis 106 2013 274 286
12. S.E. Gollust, L. Attanasio, A. Dempsey, A.M. Benson, and E.F. Fowler Political and news media factors shaping public awareness of the HPV vaccine Womens Health Issues 23 2013 e143 e151
13. L.J. Rutten, E.M. Augustson, K.A. Doran, R.P. Moser, and B.W. Hesse Health information seeking and media exposure among smokers: a comparison of light and intermittent tobacco users with heavy users Nicotine Tob Res 11 2009 190 196
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344:1383-9.
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 1998; 339:1349-57.
16. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
17. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group N Engl J Med 333 1995 1301 1307
18. M.J. Chapman, H.N. Ginsberg, and P. Amarenco Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
19. J. Perk, G. De Backer, and H. Gohlke European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
20. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
21. A.P. Mitchell, and R.J. Simpson Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States BMC Res Notes 5 2012 373
22. A. Morrison, and H. Glassberg Determinants of the cost-effectiveness of statins J Manag Care Pharm 9 2003 544 551
23. M.J. Pletcher, L. Lazar, and K. Bibbins-Domingo Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering Ann Intern Med 150 2009 243 254
24. P. Tuppin, A. Neumann, and N. Danchin Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization Arch Cardiovasc Dis 103 2010 363 375